The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Slyusar T.A.

Tver State Medical University

Abramenko Yu.V.

Tver State Medical University

Slyusar I.N.

Tver State Medical University

Abramova V.N.

Tver Regional Hospital

Antoshina A.B.

Tver State Medical University

Personal characteristics of patients with cerebral microangiopathy

Authors:

Slyusar T.A., Abramenko Yu.V., Slyusar I.N., Abramova V.N., Antoshina A.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3): 51‑56

DOI: 10.17116/jnevro202512503151

Read: 1004 times

Buy for 300₽
Contact the author
Table of contents

PERSONAL CHARACTERISTICS OF PATIENTS WITH CEREBRAL MICROANGIOPATHY
PERSONAL CHARACTERISTICS OF PATIENTS WITH CEREBRAL MICROANGIOPATHY

To cite this article:

Slyusar TA, Abramenko YuV, Slyusar IN, Abramova VN, Antoshina AB. Personal characteristics of patients with cerebral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3):51‑56. (In Russ.)
https://doi.org/10.17116/jnevro202512503151

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Arte­rial hype­rtension is an oxidative stress, as a pathogenetic target for the treatment of chro­nic cere­brovascular insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
Animal expe­rimental models in the study of age-dependent cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):57-68
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):15-24
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
The impact of Mexi­dol on improving quality of life para­meters and functional kidney status as part of complex therapy for cognitive impairments in como­rbid patients with microalbuminuria against the background of arte­rial hype­rtension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478
Abstract:

OBJECTIVE

To study the personality characteristics of patients with cerebral microangiopathy (CMA) and evaluate the effect of sequential therapy with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on the personal characteristics of patients with CMA.

MATERIAL AND METHODS

130 patients aged 55—70 years (72 women and 58 men) with CMA, who received Mexidol as part of the complex treatment according to the specified scheme. The neuropsychological study included the study of personality traits using the multifactorial personality questionnaire of R. Cattell and the Freiburg personality questionnaire, MRI. The neuropsychological examination included the study of personality characteristics using the R. Cattell multifactorial personality research questionnaire (form C) and the Freiburg Personality Questionnaire (variant B).

RESULTS

Patients with CMA were characterized by heterogeneity of personality characteristics, the severity and diversity of which changed as the disease progressed. The course of treatment with Mexidol led to a decrease in the representation and severity of personality changes.

CONCLUSION

The high efficacy and safety of long-term sequential therapy with Mexidol and Mexidol FORTE 250 has been demonstrated.

Keywords:

cerebral microangiopathy
personality
Cattell test
Freiburg personality questionnaire
Mexidol

Authors:

Slyusar T.A.

Tver State Medical University

Abramenko Yu.V.

Tver State Medical University

Slyusar I.N.

Tver State Medical University

Abramova V.N.

Tver Regional Hospital

Antoshina A.B.

Tver State Medical University

Received:

16.12.2024

Accepted:

18.12.2024

Close metadata

References:

  1. Kadjikov AS, Manvelov LS, Shahparonova NV. Chronic vascular diseases of the brain encephalopathy. Guide for doctors. 3rd edition, revised and expanded. M.: GEOTAR-Media. 2014. (In Russ.).
  2. Kalinkin MN, Yakovlev NA, Slyusar TA. Chronic cerebral ischemia in old age (pathogenetic and clinical aspects). Tver: RITs TGMU. 2016. (In Russ.).
  3. Golubev MV, BukharovYaM, Golovkin IS. Efficiency of psychotherapy in early forms of chronic cerebrovascular insufficiency (chronic cerebral ischemia). Practical Neurology and Neurorehabilitation. 2007;2:35-40. (In Russ.).
  4. Kiparisova ES, Kuzmenko VA, Mikhailova IS, et al. Current recommendations for the diagnosis and treatment of cerebrovascular insufficiency. M.: MEDpress. 2015. (In Russ.).
  5. Soloviev AG, Novikova IA, Mestechko VV. Psychosocial characteristics of elderly people with non-psychotic mental disorders. Bekhterev Review of Psychiatry and Medical Psychology. 2013;4(7):45-50. (In Russ.).
  6. Petrova NN, Leonidova LA, Barantsevich ER, et al. Mental disorders in neurological patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;106(7):20-23. (In Russ.).
  7. Smulevich AB, Syrkin AL. Psychocardiology. M.: MIA. 2005. (In Russ.).
  8. Rostamian S, Mahinrad S, Stijnen T. Cognitive impairment and risk of stroke: a systematic review and meta-analysis of prospective cohort studies. Stroke. 2014;45(5):1342-1348.
  9. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatr. 2005;45(8):22-29. 
  10. Camus V. Geriatric depression and vascular diseases: what are the links. J Affect Disor. 2004;81:1-16. 
  11. Holley C, Murrell SA, Mast BT. Psychosocial and vascular risk factors for depression in the elderly. Am J Geriatr Psychiatry. 2006;67(1):84-90. 
  12. Altman DSh. Early forms of cerebrovascular insufficiency in atherosclerosis and arterial hypertension. Ekaterinburg: Ural Branch of the RAS. 2004. (In Russ.).
  13. Stewart JC. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch Gen Psychiatry. 2007;64(6):225-233. 
  14. Kolyagin VV. Early forms of chronic cerebral ischemia. Variants of neurasthenic-like symptoms. Types of psychogenic reactions. Fundamentals of therapy. Psychosomatic and somatoform disorders in modern clinical practice. Irkutsk: IA Press. 2005. (In Russ.).
  15. Grigorieva VN, Gustov AV, Kotova OV. The role of emotional stress in the development of initial forms of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2000;100(5):14-18. (In Russ.).
  16. Slyusar TA, AbramenkoYuV, Rubina SS, et al. Features of response to stress in elderly men and women with chronic cerebral ischemia. Medical Alphabet. Neurology and Psychiatry. 2021;5(3):12-17. (In Russ.).
  17. Zaharov VV, Tkacheva ON, Mkhitaryan EA, et al. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro202212211273
  18. Terekhina OL, Kirova YuI. The effect of ethylmethylhydroxypyridine succinate on the parameters of chronic neuroinflammation and plastic processes in the brain of old rats during course of dexamethasone administration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):115-121. (In Russ.). https://doi.org/10.17116/jnevro2024124091115
  19. Belkin AA, Belkin VA, Vasilchenko IE, et al. Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):108-117. (In Russ.). https://https://doi.org/org/10.17116/jnevro2024124041108
  20. Voronina TA Pioneer antioxidant neuroprotection. 20 years in clinical practice. Russian Medical Journal. 2016;7:434-438. (In Russ.).
  21. Duma SN. Possibilities of antioxidant therapy in asthenia and cognitive deficits in elderly patients with chronic brain ischemia. Therapeutic Archive. 2013;12:100-105. (In Russ.).
  22. Vizilo TL, Arefieva EG. Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia in outpatient settings. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(3):51-55. (In Russ.). https://doi.org/10.17116/jnevro202312303151
  23. Zhuravleva MV, Vasyukova NS, Arkhipov VV, et al. Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):1-11. (In Russ.). https://doi.org/10.17116/jnevro20221221111
  24. Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2): 87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
  25. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.).
  26. Chukanova EI, Chukanova AS. Efficiency and safety of drug Mexidol Forte 250 as part of successive therapy in patients with chronic brain ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39-45. (In Russ.).
  27. Godunova AR, Rakhimova AA, Leontyeva OI, et al. An influence of submaximal (subminimal) doses of mexidol on oxidant stress and inflammation in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2):27-30. (In Russ.). https://doi.org/org/10.17116/jnevro20181182127-30
  28. Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infectious Diseases. 2020;18(2):97-102. (In Russ.). https://doi.org/10.20953/1729-9225-2020-2-97-102
  29. Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4):28-31. (In Russ.).
  30. Yakovlev NA, Kalinkin MN, Slyusar TA. Treatment of chronic cerebral ischemia in the elderly. Tver. 2017;196. (In Russ.).
  31. Fundamentals of clinical psychology and medical psychodiagnostics. Ed. by BV. Ovchinnikov. St. Petersburg: Elbi-SPb. 2005. (In Russ.).
  32. Kapustina AN. R. Kettell’s multifactorial personal methodology. St. Petersburg: Rech. 2004;32. (In Russ.).
  33. Stolyarenko LD. Fundamentals of Psychology. Rostov-on-Don: Phoenix. 2002. (In Russ.).
  34. Seredenin SB. Genetic differences on response to emotional stress and tranquilizers. Psychopharmacol Biol Narcol. 2003;23(1):494-509. 
  35. Kholmogorova AB, Garanyan NG. The concept of alexithymia (review of foreign studies). Social and Clinical Psychiatry. 2003;1:128-145. (In Russ.).
  36. Luban-Plozza B, Peldinger V, Kroeger F. Psychosomatic disorders in general medical practice. SPb.: Piter. 2000. (In Russ.).
  37. Wasserman LI, Trifanova EA, Shchelkova OYu. Psychological diagnostics and correction in a somatic clinic. SPb.: Rech. 2011. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.